drugset / Trial / NCT01657305

Oleogel-S10 in Wound Healing of Split-Thickness Skin Graft Donor Sites (BSH-12)

NCT01657305

Phase 3 Completed 107 enrolled Birken AG
RandomizedSingle-groupSingle-blindTreatment

Summary

The main purpose of this phase III clinical trial was to compare intra-individually the efficacy, safety and tolerability of Oleogel-S10 and non-adhesive wound dressing versus non-adhesive wound dressing only in accelerating the wound healing of Split-Thickness Skin Graft (STSG) donor sites.

Timeline

Start
2012-08
Primary completion
2013-08
Completion
2014-09

Drugs

EvaluationDrugModalityDoseRoute
Subject BIRCH TRITERPENES Small molecule 100 mg Topical

Indications

No indication recorded.